Apellis Pharmaceuticals
Quarterly Financials
| Values in thousands | 2024-09-30 | 2024-06-30 | 2024-03-31 | 2023-12-31 |
|---|---|---|---|---|
Revenue | $196,830 | $199,685 | $172,325 | $146,377 |
Gross Profit | 163,273 | 176,136 | 151,672 | 126,465 |
EBITDA | -43,864 | -27,735 | -58,842 | -79,261 |
EBIT | -44,485 | -28,184 | -59,286 | -79,751 |
Net Income | -57,445 | -37,657 | -66,423 | -88,576 |
Net Change In Cash | 196,830 | 199,685 | 172,325 | 146,377 |
Free Cash Flow | 34,096 | -8,429 | -133,276 | -97,970 |
Cash | 396,864 | 361,426 | 327,026 | 352,299 |
Basic Shares | 123,904 | 123,904 | 122,957 | 121,232 |
Annual Financials
| Values in thousands | 2023-12-31 | 2022-12-31 | 2021-12-31 | 2020-12-31 |
|---|---|---|---|---|
Revenue | $396,591 | $75,422 | $66,563 | $250,646 |
Gross Profit | 338,081 | 69,786 | 61,363 | 225,596 |
EBITDA | -495,211 | -617,390 | -731,269 | -312,233 |
EBIT | -496,915 | -618,877 | -732,761 | -313,092 |
Net Income | -528,628 | -652,172 | -746,354 | -344,874 |
Net Change In Cash | 396,591 | 75,422 | 66,563 | 250,646 |
Free Cash Flow | -595,508 | -515,269 | -564,229 | -165,910 |
Cash | 351,185 | 551,801 | 640,192 | 565,779 |
Basic Shares | 118,678 | 106,114 | 84,421 | 75,163 |
Earnings Calls
| Quarter | EPS |
|---|---|
2024-09-30 | -$0.46 |
2024-06-30 | -$0.28 |
2024-03-31 | -$0.42 |
2023-12-31 | -$0.73 |
